Aldeyra Therapeutics’ shares rose 2% amid speculation of a takeover by a large pharmaceutical firm. The identity of the potential bidder is unknown. Aldeyra announced favorable safety data for its dry eye disease candidate, reproxalap, in February. The data came from a 12-month study involving 447 patients.
- Aldeyra Therapeutics (NASDAQ:ALDX) rose 2% amid takeover speculation for the eye drug company.
- Aldeyra (ALDX) may have drawn takeover interest from large pharmaceutical firm, according to a Betaville “uncooked” alert. The identity of the potential bidder wasn’t known.
- Aldeyra (ALDX) in late February announced favorable safety data for its dry eye disease candidate reproxalap from a 12-month study involving 447 patients.
Source: SeekingAlpha